Geographic trends in invasive candidiasis

Current Fungal Infection Reports

Volumn 4, Issue 4, 2010, Pages 210-218

  Nishikaku, Angela S ^a   Melo, Analy S A ^a   Colombo, Arnaldo L ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Candida albicans MLST; Candida spp.; Candidemia; Emergent Candida spp.; Emergent pathogens; Epidemiology; Nosocomial infections

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FUNGAL PROTEIN;

AGE DISTRIBUTION; ARTICLE; BIBLIOGRAPHIC DATABASE; BLOODSTREAM INFECTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CLIMATE; DIETARY INTAKE; ENVIRONMENTAL FACTOR; FUNGUS ISOLATION; GEOGRAPHIC DISTRIBUTION; GEOGRAPHICAL VARIATION (SPECIES); HOST; HUMAN; INVASIVE CANDIDIASIS; MEDLINE; MOUTH HYGIENE; NONHUMAN; NORTH AMERICA; NUTRITIONAL STATUS; PICHIA GUILLIERMONDII; SCIENTIFIC ELECTRONIC LIBRARY ONLINE; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW;

EID: 79952190965     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0033-7     Document Type: Article

References (73)

1. Almirante B, Rodriguez D, Park BJ, et al.: Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
2. Colombo AL, Nucci M, Park BJ, et al.: Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006, 44:2816-2823. (Pubitemid 44228575)
3. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163. This is a comprehensive review on the burden of candidemia and its major epidemiologic aspects.
4. Colombo AL, Thompson L, Graybill JR: The north and south of candidemia: issues for Latin America. Drugs Today (Barc) 2008, 44(Suppl A):1-34. This a comprehensive review on candidemia, contrasting the epidemiology of Latin America with that of the United States.
5. Warnock DW: Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 2007, 48:1-12.
6. Colombo AL, Nucci M, Salomao R, et al.: High rate of nonalbicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999, 34:281-286. (Pubitemid 29325040)
7. Krcmery V, Barnes AJ: Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002, 50:243-260. (Pubitemid 37554852)
8. Pfaller MA, Diekema DJ: Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004, 10(Suppl 1):11-23. (Pubitemid 38386593)
9. Gonzalez GM, Elizondo M, Ayala J: Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J Clin Microbiol 2008, 46:2902-2905. This is a large surveillance study of candidemia in Mexico.
10. Morgan J: Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005, 7:429-439.
11. Colombo AL, Guimaraes T, Silva LR, et al.: Prospective observational study of candidemia in Sao Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 2007, 28:570-576. (Pubitemid 46814547)
12. Morgan J, Meltzer MI, Plikaytis BD, et al.: Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26:540-547. (Pubitemid 40896144)
13. Horn DL, Neofytos D, Anaissie EJ, et al.: Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703. This is a large surveillance study of candidemia in the United States.
14. Asmundsdottir LR, Erlendsdottir H, Haraldsson G, et al.: Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 2008, 47:e17-e24. (Pubitemid 351920646)
15. Sullivan DJ, Moran GP, Pinjon E, et al.: Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 2004, 4:369-376. (Pubitemid 38156201)
16. Milan EP, de Laet Sant' Ana P, de Azevedo Melo AS, et al.: Multicenter prospective surveillance of oral Candida dubliniensis among adult Brazilian human immunodeficiency virus-positive and AIDS patients. Diagn Microbiol Infect Dis 2001, 41:29-35. (Pubitemid 33001456)
17. Pfaller MA, Boyken L, Hollis RJ, et al.: In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46:150-156.
18. St-Germain G, Laverdiere M, Pelletier R, et al.: Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 2008, 19:55-62. This is a large surveillance study of candidemia in Canada.
19. Borg-von Zepelin M, Kunz L, Ruchel R, et al.: Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007, 60:424-428. (Pubitemid 47243899)
20. Sandven P, Bevanger L, Digranes A, et al.: Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006, 44:1977-1981.
21. Odds FC, Hanson MF, Davidson AD, et al.: One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007, 56:1066-1075. (Pubitemid 47262669)
22. Chowdhary A, Lee-Yang W, Lasker BA, et al.: Comparison of multilocus sequence typing and Ca3 fingerprinting for molecular subtyping epidemiologically-related clinical isolates of Candida albicans. Med Mycol 2006, 44:405-417. (Pubitemid 44173324)
23. Da Matta DA, Melo AS, Guimaraes T, et al.: Multilocus sequence typing of sequential Candida albicans isolates from patients with persistent or recurrent fungemia. Med Mycol 2010, 48:757-762.
24. Odds FC, Bougnoux ME, Shaw DJ, et al.: Molecular phylogenetics of Candida albicans. Eukaryot Cell 2007, 6:1041-1052. This is a comprehensive review on molecular phylogenetics of C. albicans.
25. Takakura S, Ichiyama S, Bain JM, et al.: Comparison of Candida albicans strain types among isolates from three countries. Int J Med Microbiol 2008, 298:663-668.
26. Da Matta DA, Melo AS, Colombo AL, et al.: Candidemia surveillance in Brazil: evidence for a boundary defining an abatement of Candida albicans group two strains. J Clin Microbiol 2010, 48:3062-3067.
27. Wingard JR, Merz WG, Rinaldi MG, et al.: Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993, 37:1847-1849. (Pubitemid 23265540)
28. Pfaller MA, Messer SA, Boyken L, et al.: Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol 2003, 41:2176-2179. (Pubitemid 36576559)
29. Pfaller MA, Messer SA, Boyken L, et al.: Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004, 42:3142-3146. (Pubitemid 38938071)
30. Lin MY, Carmeli Y, Zumsteg J, et al.: Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005, 49:4555-4560. (Pubitemid 41552584)
31. Alcoba-Florez J, Mendez-Alvarez S, Cano J, et al.: Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol 2005, 43:4107-4111. (Pubitemid 41129706)
32. Correia A, Sampaio P, James S, Pais C: Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int J Syst Evol Microbiol 2006, 56:313-317. (Pubitemid 43125932)
33. Borman AM, Petch R, Linton CJ, et al.: Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol 2008, 46:933-938. (Pubitemid 351379982)
34. Lockhart SR, Messer SA, Gherna M, et al.: Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol 2009, 47:1216-1217. This is a reference paper for molecular identification of C. glabrata and related species.
35. Trofa D, Gacser A, Nosanchuk JD: Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008, 21:606-625.
36. Colombo AL, Ngai AL, Bourque M, et al.: Caspofungin use in patients with invasive candidiasis caused by common nonalbicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother 2010, 54:1864-1871.
37. Tavanti A, Davidson AD, Gow NA, et al.: Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005, 43:284-292. (Pubitemid 40096313)
38. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ: Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008, 46:2659-2664. This is a reference paper for molecular identification of the C. parapsilosis complex.
39. Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D, et al.: Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008, 52:1506-1509. (Pubitemid 351522020)
40. Gonçalves SS, Amorim CS, Nucci M, et al.: Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect 2009, 16:885-887.
41. Silva AP, Miranda IM, Lisboa C, et al.: Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 2009, 47:2392-2397.
42. Nucci M, Colombo AL: Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis 2007, 58:77-82. This is a comprehensive review of the epidemiology of C. tropicalis candidemia.
43. Jung SI, Shin JH, Song JH, et al.: Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol 2010, 48:669-674.
44. Mokaddas EM, Al-Sweih NA, Khan ZU: Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 2007, 56:255-259.
45. Tan TY, Tan AL, Tee NW, Ng LS: A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. Ann Acad Med Singapore 2008, 37:835-840.
46. Yang YL, Wang AH, Wang CW, et al.: Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006. Diagn Microbiol Infect Dis 2008, 61:175-180.
47. Pfaller MA, Diekema DJ, Colombo AL, et al.: Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006, 44:3578-3582. (Pubitemid 46768813)
48. Colombo AL, Melo AS, Crespo Rosas RF, et al.: Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis 2003, 46:253-257. (Pubitemid 37025761)
49. Dube MP, Heseltine PN, Rinaldi MG, et al.: Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin Infect Dis 1994, 18:77-82. (Pubitemid 24025919)
50. Pfaller MA, Diekema DJ, Gibbs DL, et al.: Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008, 46:515-521.
51. BendelCM: Colonization and epithelial adhesion in the pathogenesis of neonatal candidiasis. Semin Perinatol 2003, 27:357-364.
52. Samaranayake LP: Nutritional factors and oral candidosis. J Oral Pathol 1986, 15:61-65.
53. Knight L, Fletcher J: Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. J Infect Dis 1971, 123:371-377.
54. Bunetel L, Bonnaure-Mallet M: Oral pathoses caused by Candida albicans during chemotherapy: update on development mechanisms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996, 82:161-165. (Pubitemid 126808150)
55. Samaranayake LP, Holmstrup P: Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989, 18:554-564. (Pubitemid 20094505)
56. Budtz-Jorgensen E, Mojon P, Rentsch A, Deslauriers N: Effects of an oral health program on the occurrence of oral candidosis in a long-term care facility. Community Dent Oral Epidemiol 2000, 28:141-149.
57. Jacob LS, Flaitz CM, Nichols CM, Hicks MJ: Role of dentinal carious lesions in the pathogenesis of oral candidiasis in HIV infection. J Am Dent Assoc 1998, 129:187-194. (Pubitemid 128686458)
58. Hossain H, Ansari F, Schulz-Weidner N, et al.: Clonal identity of Candida albicans in the oral cavity and the gastrointestinal tract of pre-school children. Oral Microbiol Immunol 2003, 18:302-308. (Pubitemid 37087262)
59. Bergendal T, Holmberg K, Nord CE: Yeast colonization in the oral cavity and feces in patients with denture stomatitis. Acta Odontol Scand 1979, 37:37-45. (Pubitemid 9123099)
60. Chaffin WL: Candida albicans cell wall proteins. Microbiol Mol Biol Rev 2008, 72:495-544. This is a comprehensive review of C. albicans cell wall proteins and their role in host-pathogen interactions.
61. Tronchin G, Pihet M, Lopes-Bezerra LM, Bouchara JP: Adherence mechanisms in human pathogenic fungi. Med Mycol 2008, 46:749-772.
62. Wiesner SM, Bendel CM, Hess DJ, et al.: Adherence of yeast and filamentous forms of Candida albicans to cultured enterocytes. Crit Care Med 2002, 30:677-683. (Pubitemid 34214636)
63. Bendel CM, Hostetter MK: Distinct mechanisms of epithelial adhesion for Candida albicans and Candida tropicalis. Identification of the participating ligands and development of inhibitory peptides. J Clin Invest 1993, 92:1840-1849. (Pubitemid 23304551)
64. Cormack BP, Ghori N, Falkow S: An adhesin of the yeast pathogen Candida glabrata mediating adherence to human epithelial cells. Science 1999, 285:578-582.
65. de Groot PW, Kraneveld EA, Yin QY, et al.: The cell wall of the human pathogen Candida glabrata: differential incorporation of novel adhesin-like wall proteins. Eukaryot Cell 2008, 7:1951-1964. This study demonstrates the presence of several groups of C. glabrata adhesin-like proteins that are dependent on strain and growth stage. The putative role of these adhesins in adaptability and virulence is discussed.
66. Kutty SN, Philip R: Marine yeasts - a review. Yeast 2008, 25:465-483.
67. Boguslawska-Was E, Dabrowski W: The seasonal variability of yeasts and yeast-like organisms in water and bottom sediment of the Szczecin Lagoon. Int J Hyg Environ Health 2001, 203:451-458. (Pubitemid 32776908)
68. Woollett LL, Hedrick LR: Ecology of yeasts in polluted water. Antonie Van Leeuwenhoek 1970, 36:427-435.
69. Hagler AN,Mendonca-Hagler LC: Yeasts frommarine and estuarine waters with different levels of pollution in the State of Rio de Janeiro, Brazil. Appl Environ Microbiol 1981, 41:173-178.
70. Rocha LL, de Aguiar Cordeiro R, Cavalcante RM, et al.: Isolation and characterization of phenol-degrading yeasts from an oil refinery wastewater in Brazil. Mycopathologia 2007, 164:183-188. (Pubitemid 47397480)
71. Takakura S, Fujihara N, Saito T, et al.: National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004, 53:283-289. (Pubitemid 38239963)
72. Swinne D, Watelle M, Suetens C, et al.: A one-year survey of candidemia in Belgium in 2002. Epidemiol Infect 2004, 132: 1175-1180.
73. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al.: Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005, 43:4434-4440. (Pubitemid 41298224)